small molecule

UTEBZI

TEBIPENEM PIVOXIL HYDROBROMIDE

Loss of exclusivityFebruary 2038latest FDA-listed patent expiry

CompanyGLAXOSMITHKLINE LLC

Drug detail

Brand name	UTEBZI
Active ingredient	TEBIPENEM PIVOXIL HYDROBROMIDE
Strength	EQ 300MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	June 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
10889587	February 2038	substance, product
12226403	December 2037	product

Regulatory exclusivity

Code	Expires
GAIN	June 2036
NCE	June 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from GLAXOSMITHKLINE LLC